IVVD
Invivyd, Inc.
$1.50
+4.90%
2026-05-08
About Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Key Fundamentals
Forward P/E
-2.28
EPS (TTM)
$-0.30
ROE
-34.0%
Revenue Growth (YoY)
24.5%
Profit Margin
-98.2%
Debt/Equity
1.03
Price/Book
1.70
Beta
0.71
Market Cap
$412.9M
Avg Volume (10D)
1.7M
Recent Breakout Signals
No recent breakout signals detected for IVVD.
Recent Price Range (60 Days)
60D High
$2.04
60D Low
$1.17
Avg Volume
2.5M
Latest Close
$1.50
Get breakout alerts for IVVD
Sign up for Breakout Scanner to receive daily notifications when IVVD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Invivyd, Inc. (IVVD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IVVD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IVVD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.